
BPB-101 is a first-in-class, humanized trifunctional bispecific IgG1 antibody targeting the GARP/TGF-β complex, active TGF-β, and PD-L1, with preclinical evidence of immunomodulatory and antitumor activity. This phase Ia study aimed to assess the safety, tolerability, pharmacology, and preliminary antitumor activity of BPB-101. A modified accelerated titration design (6, 20, and 60 mg) was followed by a 3 + 3 escalation (200–1800 mg), with intravenous dosing every 3 weeks (Q3W). Eligible patients with advanced or metastatic solid tumors who had received prior standard systemic treatment were enrolled. The primary objectives were dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended phase II dose (RP2D). Secondary and exploratory objectives included pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary antitumor activity. At the data cutoff of January 26, 2025, 19 patients with advanced tumors were enrolled. Treatment-related adverse events (TRAEs) occurred in 15 patients (78.9
Myeloid/lymphoid neoplasms with FGFR1 rearrangement (MLN-FGFR1) are rare, aggressive hematologic malignancies for which allogeneic hematopoietic cell transplantation (allo-HCT) remains the only potentially curative option. Pemigatinib, a reversible FGFR1-3 inhibitor, has substantial activity in chronic phase but lower efficacy in blast phase (BP). Data on futibatinib, an irreversible FGFR1-4 inhibitor, in BP MLN-FGFR1 are lacking. We report a 60-year-old man with MLN-ZMYM2::FGFR1 presenting in myeloid BP with extensive extramedullary disease (EMD) that was clinically refractory to induction chemotherapy. Initiation of off-label futibatinib was followed by rapid clinical improvement, complete cytogenetic remission (CCyR) and complete metabolic response (CMR), enabling bridging to allo-HCT from a mismatched unrelated donor. Futibatinib was subsequently continued as post-transplant maintenance with dose escalation and later combined with donor lymphocyte infusions (DLI). At last follow-up (day +497), the patient maintained a CMR and remained in CCyR with full donor chimerism, although ZMYM2::FGFR1 transcripts were still detectable at low levels in the bone marrow by droplet digital PCR. Next-generation sequencing additionally identified a germline DDX41 variant of uncertain significance, a finding potentially relevant to donor selection. To our knowledge, this is the first report of futibatinib used both as a bridge to transplantation and as post-transplant maintenance in BP MLN-FGFR1 with EMD. Although futibatinib’s contribution cannot be separated from that of conditioning, graft-versus-leukemia activity and DLI, these hypothesis-generating findings provide support for further evaluation of irreversible FGFR1 inhibition in MLN-FGFR1.
PD-(L)1×VEGF bispecific antibodies integrate immune checkpoint blockade and VEGF inhibition within a single molecule, offering a potential strategy to overcome angiogenesis-associated immune resistance. At the 2026 ASCO Annual Meeting, the randomized phase 3 HARMONi-6 trial demonstrated an overall survival benefit with ivonescimab plus chemotherapy over tislelizumab plus chemotherapy in previously untreated advanced squamous non-small cell lung cancer (NSCLC), extending survival evidence to an active PD-1–based first-line comparator. Exploratory phase 2 studies of pumitamig, SSGJ-707, and HB0025 reported encouraging activity in first-line NSCLC, while phase 1 and 2 studies of IMM2510 and ivonescimab-based regimens suggested activity after prior immunotherapy. Smaller exploratory studies also reported activity in perioperative head and neck cancer, colorectal cancer, endometrial cancer, and mucosal melanoma. Collectively, these findings highlight the clinical potential of PD-(L)1×VEGF bispecific antibodies, with the strongest evidence in first-line squamous NSCLC and broader applications remaining hypothesis-generating. Future development should prioritize predictive biomarkers, resistance mechanisms, optimal treatment sequencing, and careful assessment of immune-related and VEGF-associated toxicities.
Pancreatic ductal adenocarcinoma (PDAC) is a near-universally lethal malignancy, with KRAS mutations driving tumorigenesis in over 90
Cancer is the second leading cause of death worldwide and disproportionately affects older adults. As population ageing accelerates, the global cancer burden among older adults continues to increase. This study systematically evaluated the latest global cancer burden and its epidemiological characteristics among older adults. Data on the incidence and mortality of 33 malignancies, excluding non-melanoma skin cancer, among adults aged 65 + were extracted from the Global Cancer Observatory (GLOBOCAN) 2024 and Global Burden of Disease Study (GBD) 2023 databases and stratified by age, sex, region, and Human Development Index (HDI). Age-standardized incidence and mortality rates (ASIR and ASMR) were calculated. Annual percentage changes (APC) were used to characterize temporal trends. Decomposition analysis was performed to quantify the contributions of population growth, population aging, and epidemiological changes. Demographic projection methods and generalized additive model (GAM) were applied to forecast the cancer burden through 2050. In 2024, there were 9,966,392 new cancer cases and 6,001,290 cancer deaths among older adults worldwide, accounting for 51.11